A soluble secreted glycoprotein (eCLCA1) is overexpressed due to goblet cell hyperplasia and metaplasia in horses with recurrent airway obstruction.
Authors: Range F, Mundhenk L, Gruber A D
Journal: Veterinary pathology
Summary
# Editorial Summary Recurrent airway obstruction (RAO) in horses involves excessive mucus production that compromises airway function, and emerging evidence implicates eCLCA1—a glycoprotein produced by airway goblet cells—as a key mediator in this pathological process. Range and colleagues compared lung tissue from nine RAO-affected horses against nine healthy controls, using immunohistochemistry and laser microdissection coupled with real-time quantitative PCR to measure both eCLCA1 protein and mRNA expression specifically within goblet cells. Whilst RAO-affected horses exhibited marked goblet cell metaplasia in bronchioles and hyperplasia in bronchi and trachea, the per-cell expression of eCLCA1 mRNA remained identical between groups, demonstrating that the elevation in total eCLCA1 is driven by increased goblet cell numbers rather than heightened gene expression within individual cells. Critically, biochemical characterisation revealed eCLCA1 functions as a secreted soluble glycoprotein incorporated into airway mucins, not as a membrane-bound channel protein as previously theorised. These findings reorient therapeutic thinking: RAO management might benefit from interventions targeting goblet cell proliferation or mucin composition itself, rather than focusing solely on ion channel modulation, and support continued investigation of eCLCA1's role in mucus hydration and rheology.
Read the full abstract on PubMed
Practical Takeaways
- •RAO involves excessive mucin production driven by abnormal increases in mucus-producing goblet cells rather than overactivity of individual cells, suggesting therapeutic targets should focus on preventing goblet cell proliferation
- •eCLCA1 functions as a secreted component of airway mucus that modulates mucin hydration; understanding this mechanism may lead to new mucoactive treatments for RAO management
- •Pathological changes in RAO are most severe in smaller airways (bronchioles), which may explain why clinical signs reflect lower airway obstruction
Key Findings
- •eCLCA1 protein expression is tightly linked to airway goblet cells in both RAO-affected and control horses
- •eCLCA1 mRNA expression per goblet cell is similar between RAO and control horses, indicating increased eCLCA1 is due to goblet cell numbers, not gene upregulation
- •eCLCA1 is a secreted glycoprotein, not an integral membrane protein as previously thought
- •RAO-affected horses show strong goblet cell metaplasia in bronchioles and hyperplasia in bronchi and trachea